SCHEMBL2769028

SCHEMBL2769028

Cc1c(CNS(=O)(=O)c2ccccc2F)nn(-c2ccccc2Cl)c1-c1ccc(Cl)cc1

nearest known ligand 0.48

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
OPRL1 P41146 6/20 0.48
KCNH2 Q12809 2/20 0.48
CNR1 P21554 9/20 0.43
LPAR5 Q9H1C0 1/20 0.42
CNR2 P34972 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL909118 0.86 CNR1 (0.47) CNR1
SCHEMBL1377778 0.83 OPRL1 (0.53) OPRL1KCNH2CNR1CNR2
SCHEMBL1380648 0.82 OPRL1 (0.60) OPRL1KCNH2CNR1LPAR5CNR2
SCHEMBL5619941 0.79 CNR1 (0.42) CNR1
SCHEMBL1380563 0.79 OPRL1 (0.47) OPRL1KCNH2CNR1CNR2
SCHEMBL1377054 0.79 OPRL1 (0.54) OPRL1KCNH2CNR1LPAR5CNR2
SCHEMBL5622086 0.79 SLC22A12 (0.44) CNR1
SCHEMBL1377828 0.78 OPRL1 (0.46) OPRL1KCNH2CNR1
SCHEMBL1377608 0.78 OPRL1 (0.60) OPRL1KCNH2CNR1CNR2
SCHEMBL2770154 0.77 OPRL1 (0.54) OPRL1KCNH2CNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1720837-B1 DERIVATIVES OF N-' (1,5-DIPHENYL-1H-PYRAZOL-3-YL) SULPHONAMIDE WITH CB1 RECEPTOR AFFINITY SANOFI AVENTIS (FR) 2010-04-28 EP claimed
US-7294645-B2 Derivatives of N′-(1,5-diphenyl-1H-pyrazol-3-yl) sulfonamide with CB1 receptor affinity SANOFI-AVENTIS (FR) 2007-11-13 US claimed
US-20070021486-A1 DERIVATIVES OF N-' (1,5-DIPHENYL-1H-PYRAZOL-3-YL) SULFONAMIDE WITH CB1 RECEPTOR AFFINITY SANOFI-AVENTIS (FR) 2007-01-25 US claimed
EP-1720837-B1 DERIVATIVES OF N-' (1,5-DIPHENYL-1H-PYRAZOL-3-YL) SULPHONAMIDE WITH CB1 RECEPTOR AFFINITY SANOFI AVENTIS (FR) 2010-04-28 EP disclosed
US-7294645-B2 Derivatives of N′-(1,5-diphenyl-1H-pyrazol-3-yl) sulfonamide with CB1 receptor affinity SANOFI-AVENTIS (FR) 2007-11-13 US disclosed
US-20070021486-A1 DERIVATIVES OF N-' (1,5-DIPHENYL-1H-PYRAZOL-3-YL) SULFONAMIDE WITH CB1 RECEPTOR AFFINITY SANOFI-AVENTIS (FR) 2007-01-25 US disclosed
EP-1720837-A1 DERIVATIVES OF N-' (1,5-DIPHENYL-1H-PYRAZOL-3-YL) SULPHONAMIDE WITH CB1 RECEPTOR AFFINITY Sanofi-Aventis (FR) 2006-11-15 EP disclosed
WO-2005073197-A1 DERIVATIVES OF N-` (1,5-DIPHENYL-1H-PYRAZOL-3-YL) SULPHONAMIDE WITH CB1 RECEPTOR AFFINITY SANOFI-AVENTIS (FR) 2005-08-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021486-A1 DERIVATIVES OF N-' (1,5-DIPHENYL-1H-PYRAZOL-3-YL) SULFONAMIDE WITH CB1 RECEPTOR AFFINITY CNR1, CNR2, NPSR1 OPRL1 4/4885KCNH2 682/4885CNR1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.